Wedge Capital Reduces Bristol Myers Squibb Stake

Institutional investor cuts position in pharmaceutical company by 3.8% in Q4 2025

Mar. 28, 2026 at 1:18pm

Got story updates? Submit your updates here. ›

Wedge Capital Management L L P NC, an institutional investor, reduced its stake in Bristol Myers Squibb Company (NYSE: BMY) by 3.8% in the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 563,410 shares of the biopharmaceutical company's stock, valued at $30.39 million as of the end of the quarter.

Why it matters

Institutional investors like Wedge Capital closely monitor their positions in major pharmaceutical companies like Bristol Myers Squibb, which develops and markets a range of drugs across multiple therapeutic areas. Changes in ownership stakes can signal shifts in market sentiment or strategic priorities for the company.

The details

According to the 13F filing, Wedge Capital sold 22,306 shares of Bristol Myers Squibb stock during the fourth quarter, reducing its total position by 3.8%. The firm now holds a $30.39 million stake in the company, making it one of Bristol Myers Squibb's institutional investors. Other hedge funds have also adjusted their positions in the stock, with some increasing and others decreasing their holdings.

  • Wedge Capital filed its 13F for the fourth quarter of 2025 on March 28, 2026.
  • The filing covers the period from October 1 to December 31, 2025.

The players

Wedge Capital Management L L P NC

An institutional investment firm that manages a portfolio of equity and fixed-income securities.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Wedge Capital's Bristol Myers Squibb position reflects the ongoing shifts in institutional investor sentiment towards the pharmaceutical industry. While the reasons behind the firm's decision are not explicitly stated, it highlights the need for investors to closely monitor changes in ownership stakes of major healthcare companies.